Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA RAHWAY, N.J., April 29, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as ...

Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases ...

SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to ...

AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel ...

prostate cancer therapy Xtandi (enzalutamide), and Inlyta (axitinib) for kidney cancer. That shift could protect the company from some of the price-cutting measures in the Inflation Reduction Act ...

for Bavencio in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib). “Strategically for Precigen, this evolution supports our vision and transition from an exclusive channel ...

Avoid co-administration. axitinib Inlyta May increase plasma concentrations of axitinib and should be avoided. crizotinib Xalkori May increase plasma concentrations of crizotinib and should be ...